SUMMARY -Th is prospective study in prevalent dialysis patients investigated prognostic properties of low triiodothyronine syndrome, protein-energy wasting and chronic infl ammation. Ninetyfour prevalent dialysis patients were followed-up for a median of 39 months. Demographic, anthropometric and biochemical parameters were collected at baseline. Univariate and multivariate analysis was done using Cox regression analysis. ROC curve analysis using survival status as a classifi cation variable was performed with the goal of determining optimal cut-off values for numerical variables. In our population, low total triiodothyronine (hazard ratio (HR) 2.19, p=0.038), catheter as vascular access (HR 2.76, p=0.023), higher vintage (HR 1.01, p=0.014) and higher Charlson comorbidity index (HR 1.28, p=0.017) were statistically signifi cantly associated with inferior survival. In our group of steady-state dialysis patients, total triiodothyronine seemed to be the strongest predictor of inferior survival among thyroid hormones. Taking this parameter into account, it was possible to identify patients at an increased risk of death even after adjustment for other prognostically relevant variables. However, after further adjustment for signifi cant risk factors, the impact of C-reactive protein and albumin on survival disappeared due to the overlapping prognostic properties. We concluded that triiodothyronine was an independent prognostic factor in our study group.
Introduction
Patients with end-stage renal disease (ESRD) are known to have a higher risk of mortality and morbidity than the general population. Risk factors for mortality in this group of patients are unique since there is a high prevalence of elderly patients with multiple comorbidities. Also, they have survived long enough to develop kidney failure. Th ere is the need to develop a special predictive model that could be applied to ESRD patients. Research has been focused on biomarkers that could be novel risk factors that increase the accuracy of prognosis in patients with ESRD 1 . One of the studied mortality risk markers in patients with ESRD is triiodothyronine (T3), whether in its free (fT3) or bound form (T3). Reduction of T3 levels, while the levels of thyroid-stimulating hormone (TSH) remain in the reference range, is known as the low T3 syndrome. It is the most frequently observed thyroid hormone alteration in ESRD patients [2] [3] [4] . Chronic kidney disease aff ects both the hypothalamus-pituitary-thyroid axis and thyroid hormone pe-ripheral metabolism. Reduction in T3 concentrations has been linked to a decrease in peripheral synthesis of T3 from thyroxine (T4) 2 . It has been shown in many survival studies so far that low T3 syndrome is a risk factor for mortality both in hemodialysis (HD) [5] [6] [7] [8] [9] and peritoneal dialysis (PD) patients 10, 11 . Another novel mortality biomarkers in ESRD patients are protein-energy wasting (PEW) and chronic infl ammation 1 . PEW is a state of decreased body stores of protein and fat masses. It can result from inadequate diet. However, in kidney disease there are some specifi c causes such as infl ammatory processes, intercurrent catabolic illnesses, nutrient losses into dialysate, metabolic acidosis, resistance to insulin, growth hormone, and insulin-like growth factor-1, hyperglucagonemia, hyperparathyroidism, and loss of blood into the hemodialyzer, into stool or by blood drawing 12 . Studies in well-characterized hemodialysis populations indicate that C-reactive protein (CRP) levels (as a marker of chronic infl ammation) are a consistent predictor of survival 1 , whereas serum albumin is known as a negative acute phase reactant, but also as one of the markers of PEW 13 . In complex processes of acute and chronic infl ammation in patients with ESRD, studies have shown strong association between infl ammation markers and low T3 syndrome, where fT3/T3 was proven to be a signifi cant and independent predictor of survival [14] [15] [16] . On the other hand, Ozen et al. showed in a large cohort of prevalent hemodialysis patients that fT3 was a strong predictor of mortality in crude and adjusted Cox models including albumin or high-sensitivity CRP (hsCRP); however, after further adjustment for both albumin and hsCRP, the impact of fT3 on mortality disappeared 17 . Another study performed by Fernández-Reyes et al. showed that low fT3 levels were not predictive of long-term mortality in a subgroup of stable HD patients, who could survive for more than 12 months 18 . Our study aimed to investigate the steady-state correlation of thyroid hormones, CRP and serum albumin (and other surrogates of PEW) with mortality in our group of dialysis patients. Furthermore, taking into account a complex mortality risk factor profi le of dialysis patients 19 , we studied correlations of available known risk factors with mortality in our patients, alongside low T3 syndrome, PEW and chronic infl ammation.
Patients and Methods

Patients
In this observational prospective cohort study, prevalent HD and PD patients treated at Sestre milosrdnice University Hospital Centre in Zagreb and Dr Tomislav Bardek General Hospital in Koprivnica, were enrolled. Baseline demographic, anthropometric and biochemical parameters were collected from April to December 2014. September 20, 2017 was considered as the end of the study. Survival was determined from the day of enrolment, with a median follow-up of 39 months. Patients were censored at transplantation or when completing the follow-up period, with no loss of follow-up in any patient. Th e study exclusion criteria were formerly diagnosed or present signs of hyperor hypothyroidism, as well as infl ammatory illness, malignancy, use of drugs that alter thyroid function (amiodarone, propranolol, lithium) and unwillingness to participate. When we began our study, there were 105 patients, but after the baseline measurements were performed, 11 patients had to be excluded due to subclinical hypothyroidism (TSH ≥5 mIU/L) and clinically unrecognized infl ammatory illness (CRP >30 mg/L). Th ere remained 94 patients, 50 (53.2%) males and 44 (46.8%) females, median age 64 years, interquartile range (IQR) 57.3-76. Patient characteristics are shown in Table 1 . Th e study protocol was approved by Ethics Committees of the Sestre milosrdnice University Hospital Centre from Zagreb and Dr Tomislav Bardek General Hospital from Koprivnica. A signed informed consent was obtained from each patient.
Methods
Hemodialysis patients were dialyzed three times weekly for four hours, through either an arteriovenous fi stula or central venous catheter, using a polysulfone dialyzer 1.6-1.8 m², bicarbonate dialysis solution with dialysate fl ow 500 mL/min and blood fl ow rate 300 mL/min. Th e Kt/V as a measure of dialysis adequacy was checked weekly and targeted above 1.2. Blood was drawn before the start of hemodialysis treatment from the inserted dialysis needle or the arterial port of dialysis circuit, before contact of blood with dialyzer and before heparin administration. Peritoneal dialysis patients were treated with four 1.5-to 2-liter exchanges four times per day using standard dialysates containing glucose and icodextrin. Using the mentioned dialysis prescription, the total Kt/V urea was aimed at minimum 1.7 per week.
At the beginning of the study, data on age, gender, type of dialysis, type of dialysis access, disease that caused ESRD, smoking habits and vintage (the length of time being treated with dialysis measured in months) were collected. Patients were measured for their body height (cm), weight (kg), body mass index (BMI, kg/m 2 ) and percentage of fat tissue (using a standard caliper, in millimeters; skinfold thickness was measured at the rear part of the upper arm, two centimeters laterally of the umbilicus and at the front part of the thigh; it was measured at the beginning of dialysis treatment, on the second dialysis in the week). Comorbidity was evaluated using modifi ed Charlson comorbidity index (a method of predicting mortality by classifying or weighting comorbidities), without patient age included, as it was considered separately.
Laboratory data obtained at the beginning of the second weekly hemodialysis session and the regular monthly check-up were considered baseline values in IQR = interquartile range; HD = hemodialysis; AV = arteriovenous; Kt/V = measure of dialysis adequacy; ESRD = end-stage renal disease; cm = centimeter; kg = kilogram; kg/m² = kilogram per cubic meter Table 2 . Baseline laboratory parameters
IQR = interquartile range; RBC = red blood count; MCV = mean corpuscular volume; WBC = white blood cell count; HDL = highdensity lipoprotein; LDL = low-density lipoprotein; UIBC = unsaturated iron binding capacity; TIBC = total iron binding capacity; CRP = C-reactive protein; PTH = parathyroid hormone; T3 = triiodothyronine; fT3 = free triiodothyronine; T4 = thyroxine; fT4 = free thyroxine; TSH = thyroid-stimulating hormone PD patients (Table 2) . Plasma analyses of thyroid hormones and TSH were performed using Abbott commercially available Abbott assays (Abbott Laboratories, Zagreb, Croatia). All other biochemical analyses were performed on an Olympus AU2700 analyzer using original Beckman Coulter assays (Beckman Coulter, Zagreb, Croatia).
Statistical analysis
Th e normality of distribution of numerical variables was tested using the Kolmogorov-Smirnov test. Normally distributed numerical variables were expressed as arithmetic mean ± standard deviation (SD), and were compared between the groups using the Ttest. Non-normally distributed numerical variables were expressed as median and IQR, and were compared between the groups using the Mann Whitney U test. Correlation between numerical variables was assessed using Pearson or Spearman correlation depending on their normality of distribution. Categorical variables were expressed as number and proportion, and were compared between the groups using the χ 2 -test or Fisher exact test when appropriate. Survival analyses were based on the Kaplan-Meier method. Univariate and multivariate analysis of factors associated with survival of patients was performed using the Cox regression analysis. ROC curve analysis using survival status as a classifi cation variable was performed to determine optimal cut-off values for numerical variables. Th e level of statistical signifi cance was set at p<0.05. All analyses were performed using the MedCalc Statistical software, version 17.8.1 (MedCalc Software bvba, Ostend, Belgium).
Results
Th yroid hormones and TSH and their clinical and laboratory correlations
Th e mean TSH value was 1.5±0.7 mIU/L. Higher TSH was statistically signifi cantly associated with lower uric acid (Rho -0.22, p=0.033), lower unsaturated iron binding capacity (UIBC) (Rho -0.25, p=0.014) and higher transferrin saturation (Rho 0.22, p=0.033). In our cohort of patients with normal TSH values, there was no statistically signifi cant association of TSH with other thyroid hormones. 
Survival of patients
Th e median follow up of our patients was 39 months. Forty-two patients died during the follow up period. Th e most common causes of death were sudden cardiac death in 17/94 (40.5%), sepsis in 17/94 (40.5%), disseminated malignant disease in 2/42 (4.8%), cerebrovascular insult in 2/42 (4.8%) patients, and hepatocellular carcinoma, myocardial infarction, suspected pulmonary embolism and unknown cause of death in one patient each. Survival curve for all patients is shown in Figure 1A . Median survival was not reached; the 3-year survival rate was 51.4%.
Optimal cut-off values with best survival discriminatory properties for thyroid hormones were determined using ROC curve analysis. Th e cut-off for TSH
Fig. 1. (A) Survival curve for all patients; (B) higher TSH; (C) lower total T3; and (D) lower fT3 were associated with inferior survival; (E) total T4; and (F) fT4 were not signifi cantly associated with survival.
*statistically signifi cant at p<0.05; TSH = thyroid-stimulating hormone; T3 = triiodothyronine; fT3 = free triiodothyronine; T4 = thyroxine; fT4 = free thyroxine; HR = hazard ratio was set at >1.8 mIU/L. Although all patients had TSH values within the reference range, patients with higher TSH values experienced shorter survival in comparison to those with lower TSH values at baseline, as shown in Figure 1B (hazard ratio (HR) 1.58, p=0.037). Both groups experienced similar survival for the period of 2 years, then survival curves started to diverge. Th e cut-off for total T3 was set at <1 nmol/L; patients with lower total T3 levels had inferior survival in comparison to patients with higher (normal) total T3 levels, as shown in Figure 1C (HR 1.97, p=0.038) . Th e cut-off for fT3 was set at >2.29 pmol/L; patients with lower fT3 similarly had inferior survival in comparison to patients with higher (normal) fT3 values, as shown in Figure 1D (HR 2.94, p=0.003). Th e cut-off values obtained for total T4 and fT4 were <86 nmol/L and >10.84 pmol/L, respectively. Total T4 (p=0.158) and fT4 (p=0.341) were not statistically signifi cantly associated with survival in our cohort of patients.
We compared prognostic properties of diff erent thyroid hormones in a Cox regression model containing TSH, total T3, fT3, total T4 and fT4, as shown in Table 3 . Low total T3 (HR 2.26, p=0.019), low fT3 (HR 2.83, p=0.005) and high-normal TSH (HR 2.03, p=0.033) each bore an independent prognostic potential as they were able to retain statistical signifi cance and predict survival independently of each other.
Other parameters that were univariately associated with survival were catheter as venous access (HR 2.44, p=0.008), age (HR 1.05, p=0.001), vintage (HR 1.01, p=0.034), Charlson comorbidity index (HR 1.39, p<0.001), body height (HR 0.07, p=0.021), albumin (HR 0.88, p=0.008) and CRP (HR 1.04, p=0.006). We further investigated prognostic properties of thyroid hormones in a Cox regression analysis model including total T3, fT3, TSH and other factors mentioned above that were univariately associated with survival and gender, as shown in Table 4 . Low total T3 (HR 2.19, p=0.038), catheter as venous access (HR 2.76, p=0.023), higher vintage (HR 1.01, p=0.014) and higher Charlson comorbidity index (HR 1.28, p=0.017) remained statistically signifi cantly associated with inferior survival.
Discussion
Study results showed that in our group of steadystate dialysis patients, total T3 seemed to be an inde- *statistically signifi cant at p<0.05; 95% CI = 95% confi dence interval; HR = hazard ratio; T3 = triiodothyronine; fT3 = free triiodothyronine; TSH = thyroid-stimulating hormone; T4 = thyroxine; fT4= free thyroxine Th e results from earlier studies showed that serum albumin and CRP were signifi cantly related with allcause mortality 13 and that the CRP levels were a consistent predictor of survival in hemodialysis populations 1 . However, in our study, after further adjustment for fT3, T3, TSH and other signifi cant confounding factors, the impact of CRP and albumin on survival disappeared due to overlapping prognostic properties. We concluded that, although it is known that low T3 syndrome and PEW are interrelated 15, 16 , in our group of patients T3 had greater infl uence on survival.
It has been recognized that all-cause and cardiovascular mortality is consistently higher in long-term dialysis patients with derangements in thyroid function test results. It is a question whether it would be cost-eff ective to screen for thyroid function among patients with ESRD 20 . When validating a potential new prognostic biomarker, there are four criteria to consider. Th e fi rst one is accuracy, which is the ability to reliably identify individuals at a greater risk of the adverse clinical outcome of interest. Th e second one is simplicity (for example, ease of measurement). Th e third one is the cost (biomarkers should be inexpensive and cost-eff ective), and the last one is the relevance of the information provided by the biomarker 21 . According to the results of our study, and to the available scientifi c information gathered so far, it is our opinion that T3 should be considered as an important novel prognostic factor that should be taken into consideration when analyzing survival chances of patients on dialysis.
Furthermore, in our study, using a central venous catheter (CVC) as vascular access in hemodialysis patients proved to be a signifi cant mortality risk factor. Th is fi nding is in accordance with the results of another study comparing diff erent types of vascular access (CVC, arteriovenous fi stulas (AVF) and arteriovenous grafts (AVG)) 22 . In this study, the survival rate among patients in whom hemodialysis was initiated with AVF was signifi cantly higher than that in patients in whom hemodialysis was initiated with AVG or CVC 22 . Patients who started hemodialysis and were using a venous catheter were at a 47% higher death risk compared with patients who were using an AVF. Th is association remained unaltered after adjustment for the potential confounding factors and after accounting for frequent changes in access type over time 23 . What is interesting about our fi nding is that, to the best of our knowledge, there has not been a study that investigated the correlation of thyroid hormones with mortality in dialysis patients, alongside other mortality risk factors, which also included the hemodialysis access. For this reason, we would suggest that hemodialysis vascular access be taken into account as an essential risk factor in the future survival studies.
Th e results of our study confi rmed once more that Charlson comorbidity index is a valid tool for assessing comorbidity burden in dialysis patients [24] [25] [26] . Also, following previous studies 27 , the dialysis vintage is a signifi cant mortality risk.
Risk prediction models can be used to inform the patients undergoing renal replacement therapy about their survival chances. Hemke et al. showed that a simple model based only on registry data could be enhanced by adding readily available clinical parameters, such as cholesterol, phosphate, and albumin 28 . Th e associations among the main risk factors for death in hemodialysis patients are complex. A study by Kanda et al. showed that simultaneous evaluation of multiple risk factors could accurately assess patient prognosis and identify patients at an increased risk of death 19 . Based on the results of our study, we agree with the conclusions of the studies above regarding the necessity of multiple mortality risk factor approach in assessing prognosis of ESRD patients.
Our study had some limitations. Th e cohort had less than 100 patients, and the median follow up of our patients was 39 months. Th e question remains whether the parameters that were statistically signifi cant would remain signifi cant if the study group was larger and the follow up longer. Furthermore, we did not consider blood pressure as a confounder. It was proven that lower blood pressure in patients on hemodialysis (predialysis systolic <110 mm Hg), as well as higher blood pressure (predialysis systolic 150-159 mm Hg) was as-sociated with higher mortality 29 . Finally, it is a question whether measures that we included in the study, such as serum albumin, BMI and percentage of fat tissue, were adequate to assess completely the presence of PEW. We were unable to assess dietary protein intake or dietary energy intake, which are considered as components of this syndrome 12 . In conclusion, T3 seems to be the most reliable predictor of inferior survival among thyroid hormones. It could identify patients at an increased risk of death even after adjustment for other prognostically relevant variables, and it should be considered as an important mortality risk factor in evaluating the prognosis of ESRD patients.
